Regeneron
Corporate investorPortfolio in United States: 5 funded startups tracked by Uback, 5 of them in a ranking.
Portfolio on Uback
Sorted by Uback rank, then Radar by last round| Company | Uback | Sector | Round backed | Valuation (AI) |
|---|---|---|---|---|
| ArsenalBio | #4 Gene & cell therapies | Healthtech › Biotech › Gene & cell therapies | Series C · USD 325M · Sep 2024 | Unicorn |
| Iambic Therapeutics | #7 AI drug discovery | Healthtech › Biotech › AI drug discovery | Equity round · over USD 100M · Nov 2025 | Unicorn |
| Tessera Therapeutics | #7 Gene & cell therapies | Healthtech › Biotech › Gene & cell therapies | Series D · USD 150–200M (sources differ) · Dec 2025 | Hundreds of M$ |
| Strand Therapeutics | #8 Gene & cell therapies | Healthtech › Biotech › Gene & cell therapies | Series B · USD 153M · Aug 2025 | Hundreds of M$ |
| Tune Therapeutics | #12 Gene & cell therapies | Healthtech › Biotech › Gene & cell therapies | Series B · USD 175M · Jan 2025 | Hundreds of M$ |
Only startups that meet Uback’s eligibility rules are shown. Amounts are round sizes, not the fund’s share. Rounds as reported by public sources.
By sector
Deals tracked per year
Co-investors
Sequoia Capital · ARK Invest · Mubadala · Qatar Investment Authority · ARCH Venture Partners · NVIDIA · T. Rowe Price · Bristol Myers Squibb · SoftBank Vision Fund · strategic · Eli Lilly · Amgen Ventures · New Enterprise Associates · Hevolution Foundation
Investors that joined the same rounds, as reported by public sources.
Sources. arsenalbio.com, biopharmadive.com, bioxconomy.com, businesswire.com, forgeglobal.com, labiotech.eu, multiples.vc, as cited on each company’s profile.
Last updated: Sep 2026Report a missing dealReport an error
Uback is a content publisher. It provides no investment advice, receives no mandate and takes part in no transaction.